Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin

Ricardo Avendano, Jorge E. Romero, Florentino Lupercio, Juan Carlos Diaz, Renato Quispe, Anjani Golive, Andrea Natale, Mario J. Garcia, Andrew K. Krumerman, Luigi Di Biase

Research output: Contribution to journalArticle

Abstract

Purpose: Amiodarone is a potent inhibitor of the CYP450:3A4 and inhibitor of the P-glycoprotein, both of which metabolize new oral anticoagulants (NOACs). Patients who are on NOACs and are concomitantly treated with amiodarone may have a higher risk of major bleeding according to recent retrospective trials. Whether this increased risk outweighs the benefits of NOACs compared to warfarin is unknown. We aimed to compare clinical outcomes between NOACs and warfarin in patients with atrial fibrillation (AF) being treated with amiodarone. Methods: We performed a systematic review of MEDLINE, Cochrane, and Embase for randomized controlled trials that compared NOACs to warfarin for prophylaxis of ischemic stroke/thromboembolic events (TEs) in patients with AF and reported outcomes on TE, major bleeding, and intracranial bleeding (ICB). Risk ratio (RR) and 95% confidence intervals were measured using the Mantel-Haenszel method. Fixed effects model was used, and if heterogeneity (I2) was > 25%, effects were analyzed using a random model. Results: A total of four studies comparing NOACs to warfarin were included in the analysis. The total number of patients on amiodarone was 6197. Mean follow up was 23 ± 5 months. No statistically significant difference for TE prevention (RR, 0.73; 95% CI 0.50–1.07), major bleeding (RR, 1.02; 95% CI 0.68–1.53), or ICB outcomes (RR, 0.58; 95% CI 0.22–1.51) between patients on NOACs + amiodarone when compared to patients on warfarin + amiodarone. Conclusion: Among patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin.

Original languageEnglish (US)
JournalJournal of Interventional Cardiac Electrophysiology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Amiodarone
Warfarin
Anticoagulants
Atrial Fibrillation
Hemorrhage
Odds Ratio
Stroke
P-Glycoprotein
MEDLINE
Randomized Controlled Trials
Confidence Intervals

Keywords

  • Amiodarone
  • Atrial fibrillation
  • Clinical outcomes
  • New oral anticoagulants
  • Vitamin K antagonists

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin. / Avendano, Ricardo; Romero, Jorge E.; Lupercio, Florentino; Diaz, Juan Carlos; Quispe, Renato; Golive, Anjani; Natale, Andrea; Garcia, Mario J.; Krumerman, Andrew K.; Di Biase, Luigi.

In: Journal of Interventional Cardiac Electrophysiology, 01.01.2018.

Research output: Contribution to journalArticle

@article{7cc0d6de451243d2920ad07fc603cc53,
title = "Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin",
abstract = "Purpose: Amiodarone is a potent inhibitor of the CYP450:3A4 and inhibitor of the P-glycoprotein, both of which metabolize new oral anticoagulants (NOACs). Patients who are on NOACs and are concomitantly treated with amiodarone may have a higher risk of major bleeding according to recent retrospective trials. Whether this increased risk outweighs the benefits of NOACs compared to warfarin is unknown. We aimed to compare clinical outcomes between NOACs and warfarin in patients with atrial fibrillation (AF) being treated with amiodarone. Methods: We performed a systematic review of MEDLINE, Cochrane, and Embase for randomized controlled trials that compared NOACs to warfarin for prophylaxis of ischemic stroke/thromboembolic events (TEs) in patients with AF and reported outcomes on TE, major bleeding, and intracranial bleeding (ICB). Risk ratio (RR) and 95{\%} confidence intervals were measured using the Mantel-Haenszel method. Fixed effects model was used, and if heterogeneity (I2) was > 25{\%}, effects were analyzed using a random model. Results: A total of four studies comparing NOACs to warfarin were included in the analysis. The total number of patients on amiodarone was 6197. Mean follow up was 23 ± 5 months. No statistically significant difference for TE prevention (RR, 0.73; 95{\%} CI 0.50–1.07), major bleeding (RR, 1.02; 95{\%} CI 0.68–1.53), or ICB outcomes (RR, 0.58; 95{\%} CI 0.22–1.51) between patients on NOACs + amiodarone when compared to patients on warfarin + amiodarone. Conclusion: Among patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin.",
keywords = "Amiodarone, Atrial fibrillation, Clinical outcomes, New oral anticoagulants, Vitamin K antagonists",
author = "Ricardo Avendano and Romero, {Jorge E.} and Florentino Lupercio and Diaz, {Juan Carlos} and Renato Quispe and Anjani Golive and Andrea Natale and Garcia, {Mario J.} and Krumerman, {Andrew K.} and {Di Biase}, Luigi",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s10840-018-0427-y",
language = "English (US)",
journal = "Journal of Interventional Cardiac Electrophysiology",
issn = "1383-875X",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin

AU - Avendano, Ricardo

AU - Romero, Jorge E.

AU - Lupercio, Florentino

AU - Diaz, Juan Carlos

AU - Quispe, Renato

AU - Golive, Anjani

AU - Natale, Andrea

AU - Garcia, Mario J.

AU - Krumerman, Andrew K.

AU - Di Biase, Luigi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: Amiodarone is a potent inhibitor of the CYP450:3A4 and inhibitor of the P-glycoprotein, both of which metabolize new oral anticoagulants (NOACs). Patients who are on NOACs and are concomitantly treated with amiodarone may have a higher risk of major bleeding according to recent retrospective trials. Whether this increased risk outweighs the benefits of NOACs compared to warfarin is unknown. We aimed to compare clinical outcomes between NOACs and warfarin in patients with atrial fibrillation (AF) being treated with amiodarone. Methods: We performed a systematic review of MEDLINE, Cochrane, and Embase for randomized controlled trials that compared NOACs to warfarin for prophylaxis of ischemic stroke/thromboembolic events (TEs) in patients with AF and reported outcomes on TE, major bleeding, and intracranial bleeding (ICB). Risk ratio (RR) and 95% confidence intervals were measured using the Mantel-Haenszel method. Fixed effects model was used, and if heterogeneity (I2) was > 25%, effects were analyzed using a random model. Results: A total of four studies comparing NOACs to warfarin were included in the analysis. The total number of patients on amiodarone was 6197. Mean follow up was 23 ± 5 months. No statistically significant difference for TE prevention (RR, 0.73; 95% CI 0.50–1.07), major bleeding (RR, 1.02; 95% CI 0.68–1.53), or ICB outcomes (RR, 0.58; 95% CI 0.22–1.51) between patients on NOACs + amiodarone when compared to patients on warfarin + amiodarone. Conclusion: Among patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin.

AB - Purpose: Amiodarone is a potent inhibitor of the CYP450:3A4 and inhibitor of the P-glycoprotein, both of which metabolize new oral anticoagulants (NOACs). Patients who are on NOACs and are concomitantly treated with amiodarone may have a higher risk of major bleeding according to recent retrospective trials. Whether this increased risk outweighs the benefits of NOACs compared to warfarin is unknown. We aimed to compare clinical outcomes between NOACs and warfarin in patients with atrial fibrillation (AF) being treated with amiodarone. Methods: We performed a systematic review of MEDLINE, Cochrane, and Embase for randomized controlled trials that compared NOACs to warfarin for prophylaxis of ischemic stroke/thromboembolic events (TEs) in patients with AF and reported outcomes on TE, major bleeding, and intracranial bleeding (ICB). Risk ratio (RR) and 95% confidence intervals were measured using the Mantel-Haenszel method. Fixed effects model was used, and if heterogeneity (I2) was > 25%, effects were analyzed using a random model. Results: A total of four studies comparing NOACs to warfarin were included in the analysis. The total number of patients on amiodarone was 6197. Mean follow up was 23 ± 5 months. No statistically significant difference for TE prevention (RR, 0.73; 95% CI 0.50–1.07), major bleeding (RR, 1.02; 95% CI 0.68–1.53), or ICB outcomes (RR, 0.58; 95% CI 0.22–1.51) between patients on NOACs + amiodarone when compared to patients on warfarin + amiodarone. Conclusion: Among patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin.

KW - Amiodarone

KW - Atrial fibrillation

KW - Clinical outcomes

KW - New oral anticoagulants

KW - Vitamin K antagonists

UR - http://www.scopus.com/inward/record.url?scp=85051821956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051821956&partnerID=8YFLogxK

U2 - 10.1007/s10840-018-0427-y

DO - 10.1007/s10840-018-0427-y

M3 - Article

JO - Journal of Interventional Cardiac Electrophysiology

JF - Journal of Interventional Cardiac Electrophysiology

SN - 1383-875X

ER -